<DOC>
	<DOC>NCT00004368</DOC>
	<brief_summary>OBJECTIVES: I. Investigate the efficacy and safety of colchicine therapy in improving hepatic function and reducing hepatic fibrosis (scarring) in children with hepatic cirrhosis.</brief_summary>
	<brief_title>Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients receive colchicine orally twice daily for 24 months. After the first month, the dose of colchicine will increase and remain at that dose for the duration of study. Patients are evaluated every 6 months during study.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Advanced hepatic fibrosis or cirrhosis in children Not pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>hepatic cirrhosis</keyword>
	<keyword>gastrointestinal disorders</keyword>
	<keyword>rare disease</keyword>
</DOC>